- recruitingPHASE1, PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
This study is testing a new drug called Etentamig for adults with multiple myeloma, a type of blood cancer. Researchers want to see if it's safe and effective when given alone or with other common treatments to help manage the disease.
United States · Australia · Israel - recruitingPHASE3
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
This study looks at a medicine called IGI to see if it can help prevent infections in adults with a type of blood cancer called multiple myeloma. Participants will either get IGI for a year or only if they develop a serious infection.
United States · Australia · Austria - active not recruitingPHASE3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
This study compares a new treatment called anitocabtagene autoleucel with standard care for people with multiple myeloma that has come back or not responded to previous treatments. It aims to see if the new treatment works better.
United States · Australia · Austria - recruitingNA
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
This study looks at adding early support care for people with multiple myeloma or aggressive lymphoma. It wants to see if this helps improve their well-being, mood, and how they feel about their care, compared to standard care alone.
Canada - recruitingPHASE3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
This study is looking at a new treatment, JNJ-79635322, for multiple myeloma, a type of blood cancer. It compares this new treatment with an existing one (Teclistamab) to see which works better for people whose cancer has returned or hasn't responded to previous treatments.
United States · Australia · Canada - recruitingPHASE1
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
This study is looking at an experimental treatment for multiple myeloma that has come back or hasn't responded to other treatments. It combines two medicines, elranatamab and iberdomide, to see how safe and effective they are together in adults.
United States · Australia · Canada - active not recruitingPHASE2
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
This study is looking at a new combination of four medicines (Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone) for people with newly diagnosed, high-risk multiple myeloma. It aims to see how safe and effective this treatment is.
Germany - active not recruitingPHASE2
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
This study looks at a new cell therapy called JNJ-68284528 for people with multiple myeloma. It aims to see how well it works in clearing up any remaining cancer cells after treatment.
United States · Belgium · France - recruitingPHASE1, PHASE2
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study is testing a new medicine called HDP-101 for people with a type of blood cancer called multiple myeloma that has come back or not responded to previous treatments. It aims to see if the medicine is safe and if it helps by slowing down or stopping the cancer.
United States · Germany · Hungary - active not recruitingPHASE3
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
This study is for people who have already been taking a medicine called venetoclax for their cancer in another trial. It allows them to keep taking venetoclax if it's helping them and they're not having bad side effects, so doctors can learn more about its long-term safety.
United States · Australia · Austria - active not recruiting
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
This study looks at how a medicine called selinexor (Nexpovio®) works for people in the UK with a blood cancer called multiple myeloma that has come back or not responded to previous treatments. It aims to understand how patients feel, how safe the treatment is, and how well it works in everyday healthcare.
Austria · Germany - recruitingPHASE3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
This study looks at new drug combinations for multiple myeloma that has come back or isn't responding to previous treatments. It compares different ways of combining talquetamab with other medicines to see which works best for people who have already tried certain common myeloma drugs.
United States · Argentina · Australia - recruitingPHASE3
Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
This study compares two treatments for multiple myeloma: iberdomide alone versus iberdomide plus isatuximab. It looks at how well these treatments reduce leftover cancer cells after a stem cell transplant, aiming to find the best long-term care.
Austria · Germany - active not recruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
This study compares a new combination treatment, teclistamab with daratumumab (Tec-Dara), against standard treatments for multiple myeloma that has come back or isn't responding well. It aims to see if the new combination works better.
United States · Argentina · Belgium - recruitingPHASE1, PHASE2
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
This study is testing a new drug, CCS1477 (also called inobrodib), for people with certain blood cancers like lymphoma, myeloma, or leukaemia. It aims to see if the drug is safe, well-tolerated, and how it works in the body.
United States · France · Spain - active not recruitingPHASE3
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments for newly diagnosed multiple myeloma. One treatment uses a drug combination followed by a cell therapy (Cilta-cel). The other uses the same drug combination followed by a stem cell transplant. The aim is to see which works best.
United States · Australia · Belgium - recruitingPHASE2
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
This study is looking for ways to prevent or reduce changes in taste that can be a side effect of medicines like talquetamab and ramantamig, which are used to treat a type of cancer called multiple myeloma.
United States · Brazil · Netherlands - active not recruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
This study looks at a new drug, Cevostamab, for people with multiple myeloma that has come back or not responded to previous treatments. It aims to check its safety, how it moves in the body, and if it helps when given alone or with other medicines.
United States · Australia · Canada - not yet recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This study looks at two drugs called dabrafenib and trametinib for various cancers with a specific gene change (BRAF V600). These drugs are already approved for some cancers and researchers want to see if they can help people with other rare cancers or cancers with this same change.
United Kingdom - recruitingPHASE1
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
This study looks at a new medicine called etentamig (ABBV-383) for multiple myeloma that has come back or isn't responding to other treatments. It aims to find out about any side effects and how it affects the disease in adults.
United States · Canada · Denmark - active not recruitingPHASE2
Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma
This study looks at a new way to treat multiple myeloma, a bone marrow cancer. It combines standard drugs with a new one called Carfilzomib. Researchers want to see if delaying a stem cell transplant works better than having one earlier, by comparing different treatment paths.
United Kingdom - recruitingPHASE1, PHASE2
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
This study is testing a new drug, Enzomenib, for people with certain types of leukaemia or blood cancers like MDS and Multiple Myeloma. It will look at its safety and how well it works, both alone and with other common treatments.
United States · Belgium · Canada - active not recruitingPHASE2
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
This study is looking at new ways to treat newly diagnosed multiple myeloma. It compares different combinations of new and existing medicines to see which ones work best to control the cancer and potentially lead to long-lasting remission.
United States · Australia · Brazil - recruiting
GMMG Multiple Myeloma Registry
This study tracks the long-term health of people in Germany who have multiple myeloma and previously took part in GMMG treatment studies. It helps researchers understand how different treatments affect patients over time, focusing on how long people live and stay well after treatment.
Germany - authorisedTherapeutic confirmatory (Phase III)
MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM
This study is looking at new ways to treat multiple myeloma, a type of blood cancer, in people under 66. It's testing if different treatment plans can better reduce the cancer to very low levels before further treatment. The aim is to find out which approaches work best for patients.
Belgium · France - recruitingPHASE2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
This study is looking at new drug combinations for people with a type of blood cancer called multiple myeloma. It aims to see how safe and effective these new treatments are, including some that might be used instead of a common transplant procedure.
Germany - recruitingPHASE1
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
This study looks at a new drug, etentamig, combined with iberdomide, for adults with multiple myeloma that has come back or not responded to previous treatments. It aims to see how safe the combination is and if it helps control the disease.
United States · Australia · Canada - active not recruitingPHASE3
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
This study compares a new treatment, Belantamab Mafodotin, with a common combination treatment (Pomalidomide and Dexamethasone) for Multiple Myeloma that has returned or not responded well to past treatments. It aims to see which treatment works better and is safer.
United States · Australia · Belgium - active not recruitingPHASE3
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This study looks at a new treatment, bb2121, for multiple myeloma that has come back or isn't responding to common medicines. It compares bb2121 with standard treatments to see which works best and is safest for patients aged 18 and over.
United States · Belgium · Canada - active not recruitingPHASE1
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
This study is testing a new medicine called teclistamab, combined with other treatments, for people with multiple myeloma. Scientists want to find the safest and best doses of these combinations to treat the disease effectively.
United States · Australia · Belgium - ongoing, recruitingTherapeutic exploratory (Phase II)
Exploratory study evaluating the relevance of [68Ga]Ga-PentixaFor for initial staging and detection of minimal residual disease in multiple myeloma patients eligible for autologous stem cell transplantation less than 66 years included in the prospective IFM 2020-02.
This study looks at a new type of scan, called [68Ga]Ga-PentixaFor, for people under 66 with multiple myeloma. It checks how well this scan finds the cancer when first diagnosed and helps track if any cancer cells remain after treatment.
France - active not recruitingPHASE1
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
This study is looking into a new treatment called MK-4002 (or HPN217) for people with multiple myeloma that has come back or is no longer responding to usual treatments. Researchers want to find a safe dose and understand how the body handles the medicine.
United States · France · Spain - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, Dose Finding Study of CC-92328 in Subjects with Relapsed and/or Refractory Multiple Myeloma.
This study is looking into a new medicine, CC-92328, for people with multiple myeloma. It's for patients whose cancer has come back or hasn't responded to other treatments. This early-stage trial aims to find the right dose of this new drug in humans.
Spain - recruitingPHASE3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
This study is for adults with a type of blood cancer called multiple myeloma that has come back or isn't responding to treatment. It compares a new medicine, etentamig, with existing treatments to see how well they control the cancer.
United States · Australia · Austria - recruiting
LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
This study looks at how new cancer treatments affect daily life for people with long-term cancer. It aims to understand how to best support them while they are on these treatments, often for many months or years.
Canada - enrolling by invitationPHASE2
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
This study is checking on people who have had a special treatment called AUTO CAR T cell therapy. Doctors want to see how these patients are doing for up to 15 years after their treatment. This helps them understand the long-term effects of this new therapy for blood cancers.
United States · United Kingdom - recruitingNA
Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment
This study looks at how special exercise programmes, called 'adapted physical activity' (APA), can help people with multiple myeloma preparing for a stem cell transplant. It hopes to find the most helpful and enjoyable exercise plan to improve their quality of life, energy levels, and overall physical health.
France - active not recruitingNA
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
This study is testing a new, easier way to give a drug called isatuximab (currently given through a drip) for people newly diagnosed with multiple myeloma who can't have a stem cell transplant. It aims to see if giving it as an injection under the skin works as well and is as safe.
France - active not recruitingPHASE1, PHASE2
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
This study is testing a new combination of medicines for multiple myeloma, a type of blood cancer. It aims to find the safest and most effective dose of Belantamab mafodotin, Nirogacestat, Lenalidomide, and Dexamethasone for people whose myeloma has returned or not responded to previous treatments.
United States · Brazil · Canada - recruitingNA
PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.
This study looks at a new care plan called PASCA for people with multiple myeloma, aged 18-70, after a stem cell transplant. It aims to see if this plan helps prevent or manage problems often linked with the condition or its treatments.
France - active not recruitingPHASE1, PHASE2
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
This study is looking into two new medicines, talquetamab and teclistamab, for people with multiple myeloma that has come back or isn't responding to other treatments. It aims to find the safest and most effective way to use them together, especially for those with hard-to-treat forms of the disease.
United States · Australia · Canada - active not recruitingPHASE1
Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma
This study looks at a new combination treatment for newly diagnosed multiple myeloma. It combines an existing drug, belantamab mafodotin, with standard treatments (VRd) to see if it's safe and effective, and to find the best dose.
United States · Australia · Canada - recruitingPHASE3
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
This study compares two treatments for newly diagnosed multiple myeloma in people who can't have a stem cell transplant. It looks at whether one combination of medicines (BRd) works better than another (DRd) to control the cancer and reduce its signs.
United States · Argentina · Australia - recruiting
Myeloma Registry Platform (MYRIAM)
The MYRIAM study in Germany is collecting information on people with multiple myeloma. It aims to understand how the disease progresses, how treatments work, and how it affects patients' lives over time. This helps doctors learn more about this cancer.
Germany - active not recruitingPHASE3
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
This study is for people with newly diagnosed multiple myeloma who have had a stem cell transplant. It compares a new medicine called elranatamab with a standard treatment, lenalidomide, to see which works better at keeping the cancer under control. It will last about five years.
United States · Australia · Austria - active not recruitingPHASE3
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This study compares two treatments for multiple myeloma that has come back or not responded to previous therapy. It aims to see if a new combination, IberDd, works better and is safer than a standard combination, DVd, for patients in the UK.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
This study is for people in the UK with multiple myeloma that has come back or not responded to previous treatments. It's testing a new combination of medicines, mezigdomide and elranatamab, to see if they are safe, what dose works best, and how well they might treat the cancer.
United States · Canada · China - not yet recruitingPHASE2
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
This study compares two treatments, Elranatamab with Lenalidomide, and Daratumumab with Lenalidomide, for people with newly diagnosed advanced blood cancer called multiple myeloma, after they've had a stem cell transplant. It aims to see which treatment works best to keep the cancer from coming back.
France - recruiting
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma
This study is looking into a drug called Zn-DDC (also known as Imuthiol) for multiple myeloma and other blood cancers. Researchers want to see how this drug, alone and with other common treatments (Lenalidomide, Pomalidomide), affects cancer cells in the lab. The goal is to find effective and affordable new treatment combinations.
United Kingdom - active not recruitingPHASE3
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
This study looks at different treatment plans for multiple myeloma after a stem cell transplant. It compares a drug called Lenalidomide with a combination of Lenalidomide and Daratumumab, to see which works best and for how long, based on how well the myeloma responds.
United States · Canada